STUDIES.
SCIENTIFIC RESEARCH
IN FOCUS.
DIRECTOR-Trial (dose-intensified re-exposure with temozolomide in alternating weeks versus temozolomide in alternating three weeks of therapy and one week off therapy in recurrent glioblastoma)
DIRECTOR-Trial (dose-intensified re-exposure with temozolomide in alternating weeks versus temozolomide in alternating three weeks of therapy and one week off therapy in recurrent glioblastoma)
In the DIRECTOR study, a 1:1 randomization between temozolomide alternating weeks and 21/28 days was performed with the aim of demonstrating superiority of temozolomide alternating weeks for the primary endpoint time to treatment failure. This is defined as time to progression, discontinuation of therapy due to toxicity or death. In addition, the influence of MGMT promoter methylation status on the study outcome was to be determined.